Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Schrodinger Inc SDGR

Technology Software - Application
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its... see more

Recent & Breaking News (NDAQ:SDGR)

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Business Wire 3 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire 8 days ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Business Wire 12 days ago

Schrödinger to Present Preclinical Data at AACR Annual Meeting

Business Wire March 25, 2025

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 18, 2025

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Business Wire March 10, 2025

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Business Wire February 26, 2025

Schrödinger to Participate in Upcoming Investor Conferences

Business Wire February 24, 2025

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 20, 2025

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

Business Wire February 12, 2025

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 22, 2025

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Business Wire January 13, 2025

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 17, 2024

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

Business Wire November 20, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 19, 2024

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Business Wire November 18, 2024

Schrödinger Reports Third Quarter 2024 Financial Results

Business Wire November 12, 2024

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Business Wire November 12, 2024

Schrödinger to Present at Jefferies London Healthcare Conference

Business Wire November 4, 2024

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Business Wire October 31, 2024